Eli Lilly and Company $LLY is Sectoral Asset Management Inc.'s 3rd Largest Position

Key Points

• Sectoral Asset Management cut its Eli Lilly stake by 22.4% in the fourth quarter, but LLY still remains its 3rd-largest position at 6.2% of holdings, worth about $7.8 million.
• Institutional ownership remains very high, with hedge funds and other institutional investors holding 82.53% of Eli Lilly shares. Several large investors, including Vanguard and Capital Research Global Investors, also increased their positions.
• Analysts remain broadly bullish: Goldman Sachs and Jefferies recently raised price targets to $1,283 and $1,330, while the company’s latest earnings beat expectations on both EPS and revenue with strong year-over-year growth.

Sectoral Asset Management Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 22.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,276 shares of the company's stock after selling 2,100 shares during the period. Eli Lilly and Company makes up 6.2% of Sectoral Asset Management Inc.'s holdings, making the stock its 3rd biggest position. Sectoral Asset Management Inc.'s holdings in Eli Lilly and Company were worth $7,819,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Capital Research Global Investors increased its holdings in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock valued at $19,141,787,000 after buying an additional 4,332,008 shares in the last quarter. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock valued at $88,087,193,000 after buying an additional 1,006,885 shares in the last quarter. Amundi increased its holdings in Eli Lilly and Company by 27.1% in the third quarter. Amundi now owns 4,525,902 shares of the company's stock valued at $3,823,977,000 after buying an additional 964,675 shares in the last quarter. Jennison Associates LLC increased its holdings in Eli Lilly and Company by 22.3% in the fourth quarter. Jennison Associates LLC now owns 5,133,676 shares of the company's stock valued at $5,517,059,000 after buying an additional 937,204 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Eli Lilly and Company by 47.6% in the third quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company's stock valued at $1,761,772,000 after buying an additional 744,868 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent analyst reports. Weiss Ratings cut shares of Eli Lilly and Company from a "buy (b)" rating to a "buy (b-)" rating in a report on Tuesday, May 19th. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a report on Thursday. Argus lifted their price objective on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a "buy" rating in a report on Monday, February 9th. Wolfe Research reaffirmed an "outperform" rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $1,220.37.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Eli Lilly and Company Stock Up 0.1%

LLY stock opened at $1,066.59 on Monday. The stock has a market capitalization of $1.00 trillion, a P/E ratio of 37.89, a P/E/G ratio of 1.16 and a beta of 0.48. The firm has a 50-day simple moving average of $942.87 and a 200-day simple moving average of $1,004.53. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company's quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the business posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's payout ratio is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.